Biomea Fusion (BMEA) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
10 Jun, 2026Opening remarks and agenda
Interim CEO called the meeting to order, welcomed shareholders, and introduced directors and officers.
Meeting held in accordance with bylaws and Delaware law; formal business outlined in the notice and proxy statement.
Independent auditors and legal counsel were present for the meeting.
Corporate governance
Record of stockholders as of April 13, 2026, was available for inspection prior to the meeting.
Louis D. Larson appointed as Inspector of Election to oversee and tabulate voting results.
Quorum confirmed with a majority of shares represented in person or by proxy.
Board and executive committee updates
Two nominees, Rainer M. Erdtmann and Eric Aguiar, MD, were nominated for Class II Director positions for a three-year term.
No stockholder nominations for directors were received; nominations declared closed.
Latest events from Biomea Fusion
- Icovamenib achieved robust HbA1c reduction and strong safety in insulin-deficient type 2 diabetes.BMEA
Study Result8 Jul 2026 - BMF-500 demonstrated early efficacy and strong safety in relapsed/refractory acute leukemia.BMEA
Study Update8 Jul 2026 - Promising diabetes therapies advance with pivotal data and partnership-driven development ahead.BMEA
Piper Sandler 37th Annual Healthcare Conference8 Jul 2026 - Phase II diabetes and obesity trials advance, with key data expected in the next 12 months.BMEA
Jefferies Global Healthcare Conference 20264 Jun 2026 - Icovamenib and BMF-650 show promise for durable diabetes and obesity treatment breakthroughs.BMEA
Corporate presentation4 Jun 2026 - Icovamenib and BMF-650 advance in trials, targeting diabetes and obesity with novel mechanisms.BMEA
H.C. Wainwright 4th Annual BioConnect Investor Conference19 May 2026 - Clinical progress and narrowed losses extend cash runway into Q1 2027, but more funding is needed.BMEA
Q1 202612 May 2026 - Icovamenib offers durable glycemic control and beta cell regeneration in diabetes.BMEA
Status update5 May 2026 - Icovamenib increased C-peptide by 52% at 12 weeks and preserved beta cell function at 1 year.BMEA
Study result29 Apr 2026